Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Amedisys, Inc. (AMED : NSDQ)
 
 • Company Description   
Amedisys Inc. provides home health and hospice services throughout the U.S. to the growing chronic, co-morbid, and aging American population. The company also offers clinically focused programs for chronic conditions and various diseases such as diabetes, coronary artery disease, congestive heart failure, orthopedics, complex wound care, geriatric surgical recovery, balance retraining, behavioral health and stroke recovery, as well as various rehabilitative programs. It provides hospice services to patients using an interdisciplinary care team comprising a physician, nurses, home health aides, social workers, therapists, dieticians, volunteers, counselors, chaplains and bereavement coordinators, when required. The company depends on reimbursement from Medicare (for chronic care) for a significant portion of its revenues on account of the age demographics of its patient base (average age of 81).

Number of Employees: 19,000

 
 • Price / Volume Information   
Yesterday's Closing Price: $97.18 Daily Weekly Monthly
20 Day Moving Average: 454,575 shares
Shares Outstanding: 32.82 (millions)
Market Capitalization: $3,189.41 (millions)
Beta: 0.94
52 Week High: $98.95
52 Week Low: $82.15
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 0.02% -4.50%
12 Week 5.91% -10.62%
Year To Date 7.04% 0.57%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
3854 AMERICAN WAY SUITE A
-
BATON ROUGE,LA 70816
USA
ph: 225-292-2031
fax: 225-292-8163
ir@amedisys.com http://www.amedisys.com
 
 • General Corporate Information   
Officers
Richard Ashworth - Chief Executive Officer
Scott G. Ginn - Chief Operating Officer; Executive Vice President
Allyson D. Guidroz - Principal Accounting Officer
Vickie L. Capps - Director
Molly Coye - Director

Peer Information
Amedisys, Inc. (CMTI)
Amedisys, Inc. (CMWLQ)
Amedisys, Inc. (AHG.)
Amedisys, Inc. (ROIX)
Amedisys, Inc. (M.DCE)
Amedisys, Inc. (DHSM)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-OUTP/HM CRE
Sector: Medical
CUSIP: 023436108
SIC: 8082
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 07/23/25
Share - Related Items
Shares Outstanding: 32.82
Most Recent Split Date: 12.00 (1.33:1)
Beta: 0.94
Market Capitalization: $3,189.41 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $1.12 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $4.90 Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: 0.00
Estmated Long-Term EPS Growth Rate: 15.02% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 07/23/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 19.83
Trailing 12 Months: 21.45
PEG Ratio: 1.32
Price Ratios
Price/Book: 2.56
Price/Cash Flow: 15.59
Price / Sales: 1.34
EPS Growth
vs. Year Ago Period: 21.36%
vs. Previous Quarter: 30.21%
Sales Growth
vs. Year Ago Period: 4.09%
vs. Previous Quarter: -0.55%
ROE
06/30/25 - -
03/31/25 - 12.52
12/31/24 - 12.14
ROA
06/30/25 - -
03/31/25 - 7.01
12/31/24 - 6.73
Current Ratio
06/30/25 - -
03/31/25 - 1.29
12/31/24 - 1.23
Quick Ratio
06/30/25 - -
03/31/25 - 1.29
12/31/24 - 1.23
Operating Margin
06/30/25 - -
03/31/25 - 6.34
12/31/24 - 6.08
Net Margin
06/30/25 - -
03/31/25 - 3.79
12/31/24 - 1.84
Pre-Tax Margin
06/30/25 - -
03/31/25 - 6.33
12/31/24 - 3.67
Book Value
06/30/25 - -
03/31/25 - 37.94
12/31/24 - 36.03
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.27
12/31/24 - 0.29
Debt-to-Capital
06/30/25 - -
03/31/25 - 21.10
12/31/24 - 22.33
 

Powered by Zacks Investment Research ©